Is Shree Ganesh Rem overvalued or undervalued?

As of 21 May 2025, the valuation grade for Shree Ganesh Remedies Ltd. has moved from very expensive to expensive, indicating a slight improvement in its perceived value. The company is currently considered overvalued based on its financial metrics. Key ratios include a PE Ratio of 34.56, an EV to EBITDA of 20.69, and a Price to Book Value of 6.00, which are significantly higher than the industry averages.
In comparison to its peer, Shree Ganesh Remedies Ltd. has a similar PE Ratio of 34.56 but maintains a higher EV to EBITDA ratio of 20.69, suggesting that it is trading at a premium relative to its peers. The company's recent stock performance has been underwhelming, with a year-to-date return of -3.61%, compared to a 5.58% gain in the Sensex, further reinforcing the notion that the stock may be overvalued in the current market environment.